The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis

Here, we identified the milk protein α-casein as a novel suppressor of tumor growth and metastasis. Briefly, Met-1 mammary tumor cells expressing α-casein showed a ~5-fold reduction in tumor growth and a near 10-fold decrease in experimental metastasis. To identify the molecular mechanism(s), we per...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cell cycle (Georgetown, Tex.) Ročník 11; číslo 21; s. 3972 - 3982
Hlavní autori: Bonuccelli, Gloria, Castello-Cros, Remedios, Capozza, Franco, Martinez-Outschoorn, Ubaldo E., Lin, Zhao, Tsirigos, Aristotelis, Xuanmao, Jiao, Whitaker-Menezes, Diana, Howell, Anthony, Lisanti, Michael P., Sotgia, Federica
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Taylor & Francis 01.11.2012
Landes Bioscience
Predmet:
ISSN:1538-4101, 1551-4005, 1551-4005
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Here, we identified the milk protein α-casein as a novel suppressor of tumor growth and metastasis. Briefly, Met-1 mammary tumor cells expressing α-casein showed a ~5-fold reduction in tumor growth and a near 10-fold decrease in experimental metastasis. To identify the molecular mechanism(s), we performed genome-wide transcriptional profiling. Interestingly, our results show that α-casein upregulates gene transcripts associated with interferon/STAT1 signaling and downregulates genes associated with "stemness." These findings were validated by immunoblot and FACS analysis, which showed the upregulation and hyperactivation of STAT1 and a decrease in the number of CD44(+) "cancer stem cells." These gene signatures were also able to predict clinical outcome in human breast cancer patients. Thus, we conclude that a lactation-based therapeutic strategy using recombinant α-casein would provide a more natural and non-toxic approach to the development of novel anticancer therapies.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current affiliation: Breakthrough Breast Cancer Research Unit; University of Manchester; Manchester, UK
ISSN:1538-4101
1551-4005
1551-4005
DOI:10.4161/cc.22227